Recent Comments

Comment RSS

Fenofibrate News and Research RSS Feed - Fenofibrate News and Research

Fenofibrate is a drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent. Also called Lofibra and TriCor.

Third-quarter financial results for the year 2009 announced by Biovail

5. November 2009 08:02
Biovail Corporation today announced financial results for the three-month and nine-month periods ended September 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these statements are based on the Company’s current views, and actual outcomes are not certain. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

Permalink | Comments (0)

Cipher Pharmaceuticals announces financial results for the third quarter of 2009

4. November 2009 07:34
Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , , ,

Permalink | Comments (0)

Cipher Pharmaceuticals to defend alleged patent infringement of CIP-TRAMADOL ER

3. November 2009 00:57
Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product. [More]

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , ,

Permalink | Comments (0)

Impax Laboratories initiates patent challenge for TRICOR

30. October 2009 11:18
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg. [More]

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , , , ,

Permalink | Comments (0)

LIVALO statin effective than simvastatin in reducing lipid levels

22. October 2009 08:44
New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Comprehensive analysis of statin drug market

21. October 2009 05:03
Reportlinker.com announces that a new market research report is available in its catalogue: Statins: The World Market, 2009-2024 [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Cipher Pharmaceuticals enrolls first patient in Phase III study of CIP-ISOTRETINOIN

7. October 2009 09:07
Cipher Pharmaceuticals Inc. today announced that it has enrolled the first patient in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. [More]

Posted in: Drug Trial News

Tags: , , , ,

Permalink | Comments (0)

Combination of LIVALO and itraconazole drugs shows no adverse reactions

2. September 2009 08:14
... [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , , , , , , , ,

Permalink | Comments (0)

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

2. September 2009 00:03
New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Aryx Therapeutics reports Q2 2009 financials

13. August 2009 19:50
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided a general business update for the second quarter ended June 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , , , ,

Permalink | Comments (0)

Diabetes-related amputations can be reduced

27. May 2009 19:34
Using fenofibrate to lower blood fats in people with diabetes reduces the risk of a first diabetes-related amputation by 36 per cent. This is among the conclusions of the FIELD study, reported in an article in this week's diabetes special issue of The Lancet. [More]

Posted in: Medical Condition News

Tags: ,

Permalink | Comments (0)

High triglyceride levels common, often untreated among Americans

23. March 2009 22:24
High concentrations of blood fats known as triglycerides are common in the United States, according to a report in the March 23 issue of Archives of Internal Medicine. [More]

Posted in: Medical Research News

Tags: , , , , , , , , ,

Permalink | Comments (0)

New treatment for diabetics identified

8. September 2008 08:24
Some of the most serious health complications associated with diabetes could be prevented or delayed by taking a widely available cholesterol-lowering drug which has already been on the market for three decades, new research has shown. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , ,

Permalink | Comments (0)

Biovail files abbreviated new drug application for Fenofibrate tablets

3. September 2008 19:50
Biovail Corporation today announced that the United States Food and Drug Administration (FDA) has accepted the Company's abbreviated new drug application (ANDA) for a generic formulation of 145mg and 48mg strengths of fenofibrate tablets (sold under the brand name Tricor by Abbott Laboratories). [More]

Posted in: Pharmaceutical News

Tags: , , ,

Permalink | Comments (0)

Fenofibrate intervention and event lowering in diabetes

6. November 2007 20:24
Fenofibrate is the first and only widely available lipid modifying agent to demonstrate significant protection to the eye of patients with type 2 diabetes, reducing the need for laser therapy in a wide spectrum of patients which should decrease the risk of progressive loss of vision. [More]

Posted in: Drug Trial News

Tags: , , , , , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.